Annual report
4021.TEDINET S100W4NI
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 24 passed
Key figures · 149
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥251.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥226.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥228.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥208.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥209.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥56.8bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥48.2bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥58.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥51.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥55.8bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥53.7bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥43.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥59.5bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥51.8bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥43.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥38.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.1bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥38.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥33.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥43.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥38.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥330.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥323.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥298.8bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥279.7bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥265.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥94.6bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥92.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥236.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥231.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥221.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥221.6bn | at 2023-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥208.1bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥200.6bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥22.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥34.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥32.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥59.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥35.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥39.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥17.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥18.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥35.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥27.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥25.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥313.26 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.82 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥291.36 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥271.88 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.73 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,711.83 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,641.4 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,557.48 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,454.36 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,384.48 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.1% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 18.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.5% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,283 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,137 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,965 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 2,737 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 2,688 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥201.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥181.2bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥183.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥170.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥162.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥47.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥40.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥49.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥45.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥46.4bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥39.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥48.7bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥44.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥36.6bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥34.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥36.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥34.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥30.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥259.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥257.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥241.8bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥231.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥225.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥80.7bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥80.5bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥178.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥177.0bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥174.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥168.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥165.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥14.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥14.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥266.46 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥248 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥256.49 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥241.21 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥212.52 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥174 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥164 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥164 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥122 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥104 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,308.32 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,277.1 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,245.72 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,188.84 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,152.93 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.6% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.1% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 136,800,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 138,800,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 141,300,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 143,000,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 145,000,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,044 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2,011 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 1,959 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 1,929 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 1,924 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 122
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | capex | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Otherother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Otherother segments | employees | at 2025-03-31 | 524 pure |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥29.2bn |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥11.4bn |
| Otherother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥17.7bn |
| Otherother segments | segment assets | at 2025-03-31 | ¥20.5bn |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥594m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥364m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥435m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥125.1bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2025-03-31 | −¥25.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥99.2bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥40.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥4.5bn |
| Agrochemicalsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Agrochemicalsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.9bn |
| Agrochemicalsreportable segment | employees | at 2025-03-31 | 749 pure |
| Agrochemicalsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥86.2bn |
| Agrochemicalsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥70.7bn |
| Agrochemicalsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥15.5bn |
| Agrochemicalsreportable segment | segment assets | at 2025-03-31 | ¥115.7bn |
| Agrochemicalsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.6bn |
| Chemicalsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Chemicalsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.9bn |
| Chemicalsreportable segment | employees | at 2025-03-31 | 376 pure |
| Chemicalsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥37.8bn |
| Chemicalsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥25.2bn |
| Chemicalsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12.7bn |
| Chemicalsreportable segment | segment assets | at 2025-03-31 | ¥33.8bn |
| Chemicalsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥179m |
| Medicinesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥446m |
| Medicinesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥409m |
| Medicinesreportable segment | employees | at 2025-03-31 | 110 pure |
| Medicinesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| Medicinesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.9bn |
| Medicinesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥92m |
| Medicinesreportable segment | segment assets | at 2025-03-31 | ¥8.6bn |
| Medicinesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Performance Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Performance Materialsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.6bn |
| Performance Materialsreportable segment | employees | at 2025-03-31 | 938 pure |
| Performance Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥100.1bn |
| Performance Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥73.6bn |
| Performance Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥26.5bn |
| Performance Materialsreportable segment | segment assets | at 2025-03-31 | ¥66.4bn |
| Performance Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥29.0bn |
| Tradingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥292m |
| Tradingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥86m |
| Tradingreportable segment | employees | at 2025-03-31 | 218 pure |
| Tradingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥117.2bn |
| Tradingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥90.4bn |
| Tradingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥26.7bn |
| Tradingreportable segment | segment assets | at 2025-03-31 | ¥44.7bn |
| Tradingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥14.3bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥13.9bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥376.5bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥277.3bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥99.2bn |
| —segment total | segment assets | at 2025-03-31 | ¥289.8bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥61.3bn |
| Otherother segments | capex | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Otherother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥748m |
| Otherother segments | revenue | 2023-04-01 → 2024-03-31 | ¥30.2bn |
| Otherother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥11.2bn |
| Otherother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥19.0bn |
| Otherother segments | segment assets | at 2024-03-31 | ¥21.1bn |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥572m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥468m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥471m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥115.8bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | −¥27.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥88.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥30.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥4.9bn |
| Agrochemicalsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥6.8bn |
| Agrochemicalsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Agrochemicalsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥82.1bn |
| Agrochemicalsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥67.4bn |
| Agrochemicalsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥14.7bn |
| Agrochemicalsreportable segment | segment assets | at 2024-03-31 | ¥119.5bn |
| Agrochemicalsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥23.4bn |
| Chemicalsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Chemicalsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Chemicalsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥35.6bn |
| Chemicalsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥23.5bn |
| Chemicalsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.1bn |
| Chemicalsreportable segment | segment assets | at 2024-03-31 | ¥33.2bn |
| Chemicalsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥48m |
| Medicinesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥473m |
| Medicinesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥367m |
| Medicinesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Medicinesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.2bn |
| Medicinesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥71m |
| Medicinesreportable segment | segment assets | at 2024-03-31 | ¥8.6bn |
| Medicinesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Performance Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥9.4bn |
| Performance Materialsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.0bn |
| Performance Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥84.6bn |
| Performance Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥67.2bn |
| Performance Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥17.4bn |
| Performance Materialsreportable segment | segment assets | at 2024-03-31 | ¥70.6bn |
| Performance Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥22.5bn |
| Tradingreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥39m |
| Tradingreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥77m |
| Tradingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥103.8bn |
| Tradingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥78.3bn |
| Tradingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥25.5bn |
| Tradingreportable segment | segment assets | at 2024-03-31 | ¥40.0bn |
| Tradingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥22.7bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥13.2bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥342.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥253.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥88.7bn |
| —segment total | segment assets | at 2024-03-31 | ¥293.0bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥53.1bn |
| Agrochemicalsreportable segment | employees | at 2025-03-31 | 567 pure |
| Chemicalsreportable segment | employees | at 2025-03-31 | 376 pure |
| Medicinesreportable segment | employees | at 2025-03-31 | 110 pure |
| Performance Materialsreportable segment | employees | at 2025-03-31 | 623 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,011
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | -25900000000 | JPY |
| Revenues from external customers | CurrentYearDuration | 251365000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | 12676000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | 26483000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 15514000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00759-000MedicinesReportableSegmentsMember | 92000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00759-000TradingReportableSegmentsMember | 26726000000 | JPY |
| Transactions with other segments | CurrentYearDuration_OtherReportableSegmentsMember | 17724000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 99218000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -99218000000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | 37835000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | 100098000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 86226000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00759-000MedicinesReportableSegmentsMember | 5993000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00759-000TradingReportableSegmentsMember | 117155000000 | JPY |
| Net sales | CurrentYearDuration_OtherReportableSegmentsMember | 29175000000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 376483000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -125118000000 | JPY |
| Net sales | CurrentYearDuration | 251365000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | 179000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | 28980000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 25571000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00759-000MedicinesReportableSegmentsMember | 1893000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00759-000TradingReportableSegmentsMember | 4089000000 | JPY |
| Operating income | CurrentYearDuration_OtherReportableSegmentsMember | 594000000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 61308000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -4475000000 | JPY |
| Operating income | CurrentYearDuration | 56833000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | 33821000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | 66418000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 115709000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00759-000MedicinesReportableSegmentsMember | 8592000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00759-000TradingReportableSegmentsMember | 44729000000 | JPY |
| Assets | CurrentYearInstant_OtherReportableSegmentsMember | 20544000000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 289814000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 40948000000 | JPY |
| Assets | CurrentYearInstant | 330763000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | 2944000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | 6551000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 2872000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00759-000MedicinesReportableSegmentsMember | 409000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00759-000TradingReportableSegmentsMember | 86000000 | JPY |
| Depreciation segment information | CurrentYearDuration_OtherReportableSegmentsMember | 1020000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | 13884000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 435000000 | JPY |
| Depreciation segment information | CurrentYearDuration | 14319000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00759-000ChemicalsReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00759-000PerformanceMaterialsReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E00759-000AgrochemicalsReportableSegmentsMember | 36000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |